Skip to main content

Tekmira Amends Deal with Hana Biosciences for Non-RNAi Legacy Products

Premium

Tekmira Pharmaceuticals said this week that it has amended its licensing deal with Hana Biosciences for three non-RNAi chemotherapy drug candidates in a move that will eliminate future payments to former debt holders.

In 2006, Tekmira licensed the legacy products to Hana, which assumed all expenses associated with their development in exchange for milestones and royalties. Under the terms of the amended deal, Hana will make a $5.75 million payment to Tekmira, which has agreed to reduce certain future payments associated with the drugs.

Tekmira said it would transfer the money to former debt holders in order to eliminate future payments to these debt holders.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.